© 2005-2012 American Society of Clinical Oncology (ASCO). All rights reserved worldwide.
Two studies showed that treatment with targeted therapy drugs (drugs that target the faulty genes and proteins that contribute to cancer growth) slowed the growth and spread of advanced NSCLC. These studies include:
- Adding the drug erlotinib (Tarceva) to follow-up treatment with the drug bevacizumab (Avastin)
- Adding the drug vandetanib (Zactima) to standard chemotherapy with docetaxel (Taxotere)
For More Information